Although interleukin-1 (IL-1) inhibitors like anakinra, rilonacept and canakinumab do not form a part of guideline-based clinical treatment, studies have shown promising results in alcoholic hepatitis [17,18]. This evidence concerns the gene IL1B and alcoholic hepatitis.